Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma
Authors
Keywords
-
Journal
ACTA ONCOLOGICA
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2019-04-19
DOI
10.1080/0284186x.2019.1598575
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlate tumor mutation burden with immune signatures in human cancers
- (2019) Xiaosheng Wang et al. BMC IMMUNOLOGY
- Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
- (2019) Konrad Pawelczyk et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas
- (2018) Francois Ng Kee Kwong et al. HISTOPATHOLOGY
- Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients
- (2018) Lívia Rojkó et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements
- (2018) Yasuto Yoneshima et al. LUNG CANCER
- Chemotherapy induces enrichment of CD47+/CD73+/PDL1+immune evasive triple-negative breast cancer cells
- (2018) Debangshu Samanta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
- (2018) Junnan Xu et al. OncoTargets and Therapy
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma
- (2017) Min-Kyung Yeo et al. HUMAN PATHOLOGY
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
- (2017) Solange Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status
- (2017) Wen Yang et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
- (2017) Marcin Kowanetz et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients
- (2017) Daichi Fujimoto et al. Scientific Reports
- KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
- (2017) Zoltan Lohinai et al. Scientific Reports
- Reply: The PD-1–PD-L1 Axis in Chronic Obstructive Pulmonary Disease
- (2016) Karl J. Staples et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy
- (2016) Panpan Zhang et al. CANCER SCIENCE
- Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
- (2016) Lucia Festino et al. DRUGS
- High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma
- (2016) Yih-Leong Chang et al. EUROPEAN JOURNAL OF CANCER
- Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
- (2016) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations
- (2016) Koichi Saruwatari et al. LUNG CANCER
- PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
- (2016) Francesco Passiglia et al. Oncotarget
- Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
- (2016) Anja Derer et al. Frontiers in Immunology
- Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
- (2016) Jin Sheng et al. Scientific Reports
- Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection
- (2015) Ming-Sound Tsao et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma
- (2015) Zoltan Lohinai et al. Journal of Thoracic Oncology
- PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
- (2015) Mei Ji et al. Journal of Translational Medicine
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy
- (2014) Mihaly Cserepes et al. EUROPEAN JOURNAL OF CANCER
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
- (2014) Yang Zhang et al. OncoTargets and Therapy
- Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
- (2014) David A Schaer et al. Journal for ImmunoTherapy of Cancer
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
- (2010) Chuan-Yong Mu et al. MEDICAL ONCOLOGY
- Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry
- (2008) Ferenc Pinter et al. JOURNAL OF MOLECULAR DIAGNOSTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now